Effect of B-cell depletion on coreceptor switching in R5 simian-human immunodeficiency virus infection of rhesus macaques

Journal of Virology

Volumn 85, Issue 7, 2011, Pages 3086-3094

  Tasca, Silvana ^a   Zhuang, Ke ^a   Gettie, Agegnehu ^a   Knight, Heather ^b   Blanchard, James ^c   Westmoreland, Susan ^b   Cheng Mayer, Cecilia ^a  

^a AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; COMPLEMENT COMPONENT C3B RECEPTOR; RITUXIMAB; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; B CELL DEPLETION; CELL SELECTION; CONTROLLED STUDY; DISEASE COURSE; FLOW CYTOMETRY; HUMORAL IMMUNITY; IMMUNOHISTOCHEMISTRY; INFECTION SENSITIVITY; LENTIVIRINAE; MACACA; NONHUMAN; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR SWITCHING; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN HUMAN IMMUNODEFICIENCY VIRUS; VIRUS NEUTRALIZATION;

ANIMALS; B-LYMPHOCYTES; HIV; HUMANS; LYMPHOCYTE DEPLETION; MACACA MULATTA; RECEPTORS, VIRUS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL TROPISM;

ANIMALIA; MACACA; MACACA MULATTA; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 79952585156     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02150-10     Document Type: Article

References (47)

1. Ahuja, A., et al. 2007. Depletion of B cells in murine lupus: efficacy and resistance. J. Immunol. 179:3351-3361.
2. Appay, V., D. C. Douek, and D. A. Price. 2008. CD8+ T-cell efficacy in vaccination and disease. Nat. Med. 14:623-628.
3. Berger, E. A., P. M. Murphy, and J. M. Farber. 1999. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:657-700.
4. Berkowitz, R. D., et al. 1998. CCR5- and CXCR4-utilizing strains of human immunodeficiency virus type 1 exhibit differential tropism and pathogenesis in vivo. J. Virol. 72:10108-10117. (Pubitemid 28520881)
5. Blaak, H., et al. 2000. In vivo HIV-1 infection of CD45RA(+)CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T-cell decline. Proc. Natl. Acad. Sci. U. S. A. 97:1269-1274.
6. Bou-Habib, D. C., et al. 1994. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J. Virol. 68:6006-6013. (Pubitemid 24258617)
7. Bunnik, E. M., L. Pisas, A. C. van Nuenen, and H. Schuitemaker. 2008. Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J. Virol. 82:7932-7941.
8. Cao, J., et al. 1997. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J. Virol. 71:9808-9812. (Pubitemid 27492434)
9. Chesebro, B., K. Wehrly, J. Nishio, and S. Perryman. 1996. Mapping of independent V3 envelope determinants of human immunodeficiency virus type 1 macrophage tropism and syncytium formation in lymphocytes. J. Virol. 70:9055-9059. (Pubitemid 26378498)
10. Cocchi, F., et al. 1996. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat. Med. 2:1244-1247.
11. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
12. Connor, R. I., K. E. Sheridan, D. Ceradini, S. Choe, and N. R. Landau. 1997. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185:621-628.
13. Daar, E. S., et al. 2007. Baseline HIV type 1 coreceptor tropism predicts disease progression. Clin. Infect. Dis. 45:643-649.
14. Dalgleish, A. G., et al. 1984. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312:763-767. (Pubitemid 15195924)
15. De Jong, J. J., A. De Ronde, W. Keulen, M. Tersmette, and J. Goudsmit. 1992. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J. Virol. 66:6777-6780.
16. Delwart, E. L., and C. J. Gordon. 1997. Tracking changes in HIV-1 envelope quasispecies using DNA heteroduplex analysis. Methods 12:348-354.
17. Deng, H., et al. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666. (Pubitemid 26197679)
18. Doms, R. W., and J. P. Moore. 2000. HIV-1 membrane fusion: targets of opportunity. J. Cell Biol. 151:F9-F14.
19. Fouchier, R. A., et al. 1992. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J. Virol. 66:3183-3187.
20. Gaufin, T., et al. 2009. Effect of B-cell depletion on viral replication and clinical outcome of simian immunodeficiency virus infection in a natural host. J. Virol. 83:10347-10357.
21. Gong, Q., et al. 2005. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174:817-826. (Pubitemid 40094277)
22. Goulder, P. J., and D. I. Watkins. 2008. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat. Rev. Immunol. 8:619-630.
23. Ho, S. H., et al. 2007. Coreceptor switch in R5-tropic simian/human immunodeficiency virus-infected macaques. J. Virol. 81:8621-8633.
24. Ho, S. H., N. Trunova, A. Gettie, J. Blanchard, and C. Cheng-Mayer. 2008. Different mutational pathways to CXCR4 coreceptor switch of CCR5-using simian-human immunodeficiency virus. J. Virol. 82:5653-5656. (Pubitemid 351705273)
25. Hwang, S. S., T. J. Boyle, H. K. Lyerly, and B. R. Cullen. 1991. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 253:71-74.
26. Koot, M., et al. 1993. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann. Intern. Med. 118:681-688.
27. Koot, M., et al. 1999. Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J. Infect. Dis. 179:254-258.
28. Lund, F. E., and T. D. Randall. 2010. Effector and regulatory B cells: modulators of CD4(+) T-cell immunity. Nat. Rev. Immunol. 10:236-247.
29. Malenbaum, S. E., et al. 2000. The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors. J. Virol. 74:11008-11016. (Pubitemid 32223966)
30. Mao, H., et al. 2005. CD8+ and CD20+ lymphocytes cooperate to control acute simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys: modulation by major histocompatibility complex genotype. J. Virol. 79:14887-14898. (Pubitemid 41636286)
31. Miller, C. J., et al. 2007. Antiviral antibodies are necessary for control of simian immunodeficiency virus replication. J. Virol. 81:5024-5035. (Pubitemid 46744414)
32. Moore, J. P., and D. D. Ho. 1995. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS 9(Suppl. A):S117-S136.
33. Moore, J. P., S. G. Kitchen, P. Pugach, and J. A. Zack. 2004. The CCR5 and CXCR4 coreceptors - central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retrovir. 20:111-126.
34. Moyle, G. J., et al. 2005. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J. Infect. Dis. 191:866-872.
35. Pantophlet, R., and D. R. Burton. 2006. GP120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 24:739-769.
36. Polzer, S., M. T. Dittmar, H. Schmitz, and M. Schreiber. 2002. The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization. Virology 304:70-80. (Pubitemid 36062833)
37. Regoes, R. R., and S. Bonhoeffer. 2005. The HIV coreceptor switch: a population dynamical perspective. Trends Microbiol. 13:269-277. (Pubitemid 40779815)
38. Ren, W., et al. 2010. Different tempo and anatomic location of dual-tropic and X4 virus emergence in a model of R5 simian-human immunodeficiency virus infection. J. Virol. 84:340-351.
39. Scarlatti, G., et al. 1997. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat. Med. 3:1259-1265.
40. Schmitz, J. E., et al. 2003. Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. J. Virol. 77:2165-2173. (Pubitemid 36110029)
41. Shioda, T., J. A. Levy, and C. Cheng-Mayer. 1991. Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature 349:167-169. (Pubitemid 21912038)
42. Shioda, T., J. A. Levy, and C. Cheng-Mayer. 1992. Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U. S. A. 89:9434-9438.
43. Tasca, S., S. H. Ho, and C. Cheng-Mayer. 2008. R5X4 viruses are evolutionary, functional, and antigenic intermediates in the pathway of a simianhuman immunodeficiency virus coreceptor switch. J. Virol. 82:7089-7099. (Pubitemid 351977727)
44. Taylor, R. P., and M. A. Lindorfer. 2008. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr. Opin. Immunol. 20:444-449.
45. Wei, X., et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312. (Pubitemid 36378357)
46. Wyatt, R., et al. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705-711. (Pubitemid 28289663)
47. Zhuang, K., et al. 2010. Adaptation to use low levels of the CD4 receptor is an early event in the process of co-receptor switching in R5 SHIV-infected rapid progressors. Abstr. 17th Conf. Retrovir. Opportun. Infect., abstr. 272.